Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-mark

Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders

SAN DIEGO--(BUSINESS WIRE)---- $RGNX #BiotechInvesting--Johnson Fistel, PLLP is investigating potent

REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following as

HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers t

Regenxbio is rated a 'risky buy' due to high volatility, regulatory setbacks, and significant near-t

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli PR Newswire ROCKVILLE, Md

ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appo

Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the pr

SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating REGENXBIO Inc. (N

Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular sess

US stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jum

Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial

Regenxbio stock drops over 23% following an FDA clinical hold on its Hunter Syndrome gene therapy RG

Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-ma

Regenxbio said on ​Monday the U.S. Food ‌and Drug Administration has placed its experimental gene th

REGENXBIO Inc. (NASDAQ:RGNX) today provided an update on its investigational gene therapy, RGX-121 (

ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update

Regenxbio Inc. delivered a strong quarter, driven by milestone revenue, with GAAP EPS of $0.43 and r

Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these s

HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers t

Wall Street analysts changed outlook on top names. For rating changes, check our analyst ratings pag

Top Wall Street analysts changed outlook on top names. For all changes & stock ratings, see anal

REGENXBIO NASDAQ: RGNX reported second-quarter 2026 progress across its late-stage gene-therapy pipe

Barclays analyst Eliana Merle downgrades Regenxbio (NASDAQ:RGNX) from Overweight to Equal-Weight

REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript

Regenxbio (RGNX) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Es

Regenxbio (NASDAQ:RGNX) reported quarterly earnings of $0.43 per share which beat the analyst consen

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potenti

ROCKVILLE, Md., Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it w

ABR, ARDX and RGNX have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2026.

NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refin

REGENXBIO Inc. (NASDAQ:RGNX) on Saturday shared long-term clinical trial findings for its experiment

REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alo

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinop

Nasdaq falls over 200 points, Dow down 0.28%, S&P 500 drops 0.51%. Energy shares up 1.4%, commun

Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s

U.S. stock futures lower, Nasdaq 100 down 2%. Intuitive Surgical shares dip 11.3% after Q2 earnings

NFLX: 10% | Netflix shares are trading lower after the company reported worse-than-expected Q2 sales

The gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts and c

Callan JMB Inc (CJMB) shares jumped 63.8% in pre-market trading after announcing a strategic partner

Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-

REGENXBIO Inc. (NASDAQ:RGNX) today announced that it intends to offer and sell, subject to market co

New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Societ

Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D

HC Wainwright & Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:RGNX) with a Buy and maintai

Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator

Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the pr

Leerink Partners analyst Mani Foroohar maintains Regenxbio (NASDAQ:RGNX) with a Outperform and ra